Harnessing deep learning
to prevent blindness
Learn how Eyenuk can help
May 17, 2022 – Meritus Health, the largest provider of healthcare in western Maryland, recently adopted the EyeArt® artificial intelligence (AI) system for autonomous diabetic retinopathy testing in its primary care clinics. The Hagerstown, MD-based…
March 21, 2022 – University of Utah Health, provider of care to patients in Utah and the broader Mountain West region and home to the only academic medical center in the state of Utah, recently…
Eyenuk Joins the Population Health Alliance, Paving Way for Autonomous AI to Improve Diabetes Complications
Harnessing Artificial Intelligence, Eyenuk is Focused on Improving Population Health Outcomes by Bringing Diabetes Complication Management to Point-of-Care and Community Settings WASHINGTON, March 10, 2022 – Population Health Alliance (PHA), the industry’s only multi-stakeholder…
EyeArt is the first FDA cleared AI technology for autonomous detection of both more than mild and vision-threatening diabetic retinopathy. The EyeArt® AI Eye Screening System is the most extensively validated autonomous AI technology, tested on over half a million patient visits globally with over two million images collected in real-world clinical environments.
* EyeArt® has US FDA clearance, CE marking as a class IIa medical device in the European Union, and a Health Canada license.
How can EyeArt Help?
The EyeArt system provides automated diabetic retinopathy screening without the need for expert human grading or eye dilation, enabling imaging, grading and reporting in a single office visit.
What does EyeArt Do?
The EyeArt system autonomously analyzes patient's retinal images acquired using an integrated fundus camera, robustly detects signs of disease, and returns an easy-to-read report in under 60 seconds.
How does EyeArt Work?
The EyeArt system incorporates a number of deep learning and image analysis algorithms to automatically assess the quality of the images, detect the presence and extent of lesions, and determine level of disease based on internationally recognized clinical scales.
Why choose EyeArt?
The EyeArt system is the world’s most-validated artificial intelligence (AI) screening tool for diabetic retinopathy, demonstrating high real-world sensitivity and specificity. It is proven to be safe, fast, and consistent.
Exceptional Performance in Pivotal, Prospective, Multi-Center Clinical Trial
EyeArt System Achieved High Accuracy for Detecting More-than-mild DR (96% Sensitivity , and 88% Specificity) and Vision-threatening DR (97% Sensitivity and 90% Specificity) and 98% Imageability, While Meeting All Primary Endpoints with p<0.0001
Dr. Jennifer I. Lim, MD, Marion H. Schenk Esq. Chair, Professor of Ophthalmology, and Director of Retina Service at the University of Illinois at Chicago presented the Eyenuk Clinical Trial study results at the ARVO 2019 Imaging in the Eye Conference in Vancouver, Canada. Dr. Lim spoke to MD Magazine about the study in a multi part interview series. Click on the video to watch the interview.